Biomarkers in AL amyloidosis: is the summit in sight?

Wechalekar, Ashutosh

doi:10.1182/blood-2018-02-832113

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GFD-15 is currently emerging as a marker with potential "unifying" function with prognostic value for survival, risk for dialysis, and treatment response [11]. It is elevated in >90% of all patients at diagnosis and it is a marker of poor overall outcome independent of other cardiac biomarkers (more than two thirds of patients with GDF-15 > 7575 pg/mL die within one year of diagnosis).…”

Section: Osteopontinmentioning

confidence: 99%

“…Given disease complexity, biomarkers have gained importance over recent years, as accurate estimates of prognosis and subsequent disease monitoring are necessary. A biomarker that entails all aspects of the disease in a sensitive but also specific manner (cardiac damage, renal failure, monoclonal plasma cell burden, and toxic free light chain circulation) is missing [11]. A number of new biomarkers have been reported in recent years and although none has made it to everyday clinical practice or has been incorporated in clinical trial design, emerging new data is promising.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in AL Amyloidosis

Fotiou

Theodorakakou

Kastritis

2021

IJMS

View full text Add to dashboard Cite

Systemic AL amyloidosis is a rare complex hematological disorder caused by clonal plasma cells which produce amyloidogenic immunoglobulins. Outcome and prognosis is the combinatory result of the extent and pattern of organ involvement secondary to amyloid fibril deposition and the biology and burden of the underlying plasma cell clone. Prognosis, as assessed by overall survival, and early outcomes is determined by degree of cardiac dysfunction and current staging systems are based on biomarkers that reflect the degree of cardiac damage. The risk of progression to end-stage renal disease requiring dialysis is assessed by renal staging systems. Longer-term survival and response to treatment is affected by markers of the underlying plasma cell clone; the genetic background of the clonal disease as evaluated by interphase fluorescence in situ hybridization in particular has predictive value and may guide treatment selection. Free light chain assessment forms the basis of hematological response criteria and minimal residual disease as assessed by sensitive methods is gradually being incorporated into clinical practice. However, sensitive biomarkers that could aid in the early diagnosis and that could reflect all aspects of organ damage and disease biology are needed and efforts to identify them are continuous.

show abstract

Section: Osteopontinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%